🟢 Opus Genetics is trading 6.58% up in pre-market after Phase 3 enrollment completion

Opus Genetics is trading 6.58% up in pre-market at $3.89 after renewed investor focus on its completed Phase 3 enrollment milestone for OPGx-LCA5.

• The company announced enrollment completion on August 3.
• Dosing is expected in the fourth quarter of 2026, with topline data anticipated by year-end 2027.
• No fresh August 18 announcement was identified; the move appears related to continued attention around the trial milestone.